Covid-19 cases cross 250 mark in India: Should you worry about JN.1 variant?

Q: How long will it take to read this news story?

The story "Covid-19 cases cross 250 mark in India: Should you worry about JN.1 variant?" has 932 words across 34 sentences, which will take approximately 4 - 8 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Covid-19 cases cross 250 mark in India: Should you worry about JN.1 variant?" was covered 16 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 334 news stories per day. It's most recent story was published 5 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #28868096</li><li>URL: https://pretty-looking.beamstart.com/news/covid-19-cases-cross-250-17477277989770</li></ul>

Business Standard Logo Business Standard 16h ago

Covid-19 cases cross 250 mark in India: Should you worry about JN.1 variant? - Business Standard

Quick Summary:

Doctors explain what the Covid JN.

India is witnessing a modest increase in cases, with 257 active infections reported nationwide as of May 19, according to data from the Ministry of Health and Family Welfare (MoHFW).

According to Yale Medicine, the JN.1 strain is a close relative of BA.2.86 (informally referred to as ‘Pirola’), a lineage of the Omicron variant.“A difference between BA.2.86 and JN.1 is that the latter has one mutation in its spike protein, a single change that may or may not alter any of the traits that characterise the virus, although preliminary research shows that it may provide extra immune evasion,” it added.